In summary, the results presented provide preliminary evidence of plasma tau and its phosphorylated form ptau181 as potential biomarkers for neurological diseases, especially for AD diagnosis, which may facilitate drug discovery of these diseases by selecting correct patients for clinical trials. The gene discussed is MAPT; the disease is Alzheimer disease.